<drug type="small molecule" created="2005-06-13" updated="2018-04-02">
  <drugbank-id primary="true">DB00734</drugbank-id>
  <drugbank-id>APRD00187</drugbank-id>
  <name>Risperidone</name>
  <description>Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [L1212, L1213].&#13; &#13; Risperidone inhibits dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. It is also said to block histamine receptors, and other neural receptors which are currently being studied [L1213,A1115].&#13; &#13; Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors [L1212, L1213, A1115].</description>
  <cas-number>106266-06-2</cas-number>
  <unii>L6UH7ZF8HC</unii>
  <average-mass>410.4845</average-mass>
  <monoisotopic-mass>410.211804333</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>16004936</pubmed-id>
        <citation>Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-6.</citation>
      </article>
      <article>
        <pubmed-id>19113797</pubmed-id>
        <citation>Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64.</citation>
      </article>
      <article>
        <pubmed-id>15907153</pubmed-id>
        <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
      </article>
      <article>
        <pubmed-id>19562274</pubmed-id>
        <citation>Kemp DE, Canan F, Goldstein BI, McIntyre RS: Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther. 2009 Jun;26(6):588-99. doi: 10.1007/s12325-009-0039-0. Epub 2009 Jun 26.</citation>
      </article>
      <article>
        <pubmed-id>16716128</pubmed-id>
        <citation>Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006 Jun;26(6):748-58.</citation>
      </article>
      <article>
        <pubmed-id>18537577</pubmed-id>
        <citation>Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.</citation>
      </article>
      <article>
        <pubmed-id>14610521</pubmed-id>
        <citation>Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3(6):356-61.</citation>
      </article>
      <article>
        <pubmed-id>9725965</pubmed-id>
        <citation>Acri AA, Henretig FM: Effects of risperidone in overdose. Am J Emerg Med. 1998 Sep;16(5):498-501.</citation>
      </article>
      <article>
        <pubmed-id>7531854</pubmed-id>
        <citation>Mannens G, Meuldermans W, Snoeck E, Heykants J: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994 May;114(4):566-72.</citation>
      </article>
      <article>
        <pubmed-id>7542051</pubmed-id>
        <citation>Hall H, Halldin C, Nyberg S, Farde L, Sedvall G: Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur Neuropsychopharmacol. 1995 Mar;5(1):19-25.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Atypicality of antipsychotics: A concept re-examined and re-defined</title>
        <url>https://www.researchgate.net/publication/24005224_The_%27atypicality%27_of_antipsychotics_A_concept_re-examined_and_re-defined</url>
      </link>
      <link>
        <title>Risperidone in the Treatment of Schizophrenia</title>
        <url>https://www.researchgate.net/publication/15685471_Marder_SR_Meibach_RC_Risperidone_in_the_treatment_of_schizophrenia_Am_J_Psychiatry_151_825-835</url>
      </link>
      <link>
        <title>Pharmacokinetics of Risperidone: Clinical Summary</title>
        <url>https://psychopharmacologyinstitute.com/antipsychotics/risperidone/pharmacokinetics-risperidone/</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>Risperidone belongs to the class of medications known as ​second generation atypical antipsychotics [A1114, A1115, L1213].  It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [A1115, A1116, L1212, L1213].</indication>
  <pharmacodynamics>The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders [A1115, A1116, L1212].&#13; &#13; Risperidone has high affinity binding to serotonergic 5-HT2A receptors versus dopaminergic D2 receptors in the brain [A1114, A1115].  Risperidone binds the D2 receptors with lower affinity than the traditional, first generation antipsychotic drugs, which bind with very high affinity.  A reduction in extrapyramidal symptoms in Risperidone use is attributed to its moderate affinity for dopaminergic D2 receptors [A1119, L1212, A1117].  &#13; &#13;</pharmacodynamics>
  <mechanism-of-action>Though its mechanism of action is not fully understood at this time, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [A1115, A1116, A1117]. &#13; &#13; D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations. Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect [A1119, A31773]. Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors [A1118, A1119]. Low affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided [A1118, A1119, A31771]. &#13; &#13; Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation [L1212, L1213]. The high affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is              &#13; therefore not completely inhibited [A1117, A1119]. Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. &#13; &#13; Risperidone has also been said to be an antagonist of alpha-1 (α1) alpha-2 (α2) receptors, and histamine (H1) receptors [L1212]. Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time [L1212, L1213].</mechanism-of-action>
  <toxicity>Symptoms of overdose include lethargy, dystonia/spasm, tachycardia, bradycardia, and seizures.  LD&lt;sub&gt;50&lt;/sub&gt;=57.7 mg/kg (rat, oral) and 34 mg/kg (rat, intravenous) [A1117, A1118, A1119].</toxicity>
  <metabolism>Extensively metabolized by hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone, which has approximately the same receptor binding affinity as risperidone [A1118, A31772]. Hydroxylation is dependent on debrisoquine 4-hydroxylase and metabolism is sensitive to genetic polymorphisms in debrisoquine 4-hydroxylase [A11119, A31772]. Risperidone also undergoes N-dealkylation to a lesser extent [A1119, A31772]. </metabolism>
  <absorption>Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</absorption>
  <half-life>3 hours in extensive metabolizers [A31772]&#13; Up to 20 hours in poor metabolizers [A31772]&#13;</half-life>
  <protein-binding>Risperidone, ~88% bound in human plasma; 9-hydroxyrisperidone, ~77% bound in human plasma [A31772].</protein-binding>
  <route-of-elimination>Risperidone is extensively metabolized in the liver. In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives are prolonged compared to young healthy subjects [A31772, L1214].</route-of-elimination>
  <volume-of-distribution>1 to 2 L/kg</volume-of-distribution>
  <clearance>Risperidone is cleared by the kidneys.  Clearance is decreased in the elderly and those with renal creatinine clearance of 15 mL/min to 59 mL/min, which decreases clearance by 60% [L1214].  </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.</description>
    <direct-parent>Pyridopyrimidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Pyridopyrimidines</class>
    <subclass/>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Benzisoxazoles</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Isoxazoles</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <alternative-parent>Pyridines and derivatives</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzisoxazole</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isoxazole</substituent>
    <substituent>Lactam</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridopyrimidine</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">risperdone</synonym>
    <synonym language="Spanish" coder="INN">Risperidona</synonym>
    <synonym language="Latin" coder="INN">Risperidonum</synonym>
    <synonym language="" coder="">Risperin</synonym>
    <synonym language="" coder="">Rispolept</synonym>
    <synonym language="" coder="">Rispolin</synonym>
    <synonym language="" coder="">Sequinan</synonym>
  </synonyms>
  <products>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282593</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282607</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282615</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282623</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282631</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Risperidone</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282585</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369079</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369087</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369095</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369117</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369125</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-risperidone</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02369133</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280396</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282119</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282127</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282135</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282143</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282151</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282178</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02364344</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-11</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367173</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367181</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367203</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367211</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-risperidone</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02367246</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-18</started-marketing-on>
      <ended-marketing-on>2014-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278448</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278456</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278464</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278472</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278480</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309572</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone ODT</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294478</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone ODT</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294486</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-risperidone ODT</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359065</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359073</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359103</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359057</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ipg-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359111</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454319</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359529</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359537</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359545</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359553</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359561</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-risperidone</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359588</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371766</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371774</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371782</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371790</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371804</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mar-risperidone</name>
      <labeller>Marcan Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371812</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359790</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359804</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359812</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359820</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359839</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-risperidon</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359847</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282275</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282283</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282291</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282240</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282259</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone ODT</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413485</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone ODT</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413493</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone ODT</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413507</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone ODT</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413515</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-risperidone ODT</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413523</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334372</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334380</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334399</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334402</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334410</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-risperidone</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02334429</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258439</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258447</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258455</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258463</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258471</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258498</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone ODT</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294435</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone ODT</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294443</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-risperidone ODT</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294451</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279266</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252007</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252015</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252023</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252031</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252058</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252066</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone ODT</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370697</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone ODT</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone ODT</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291770</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone ODT</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291789</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-risperidone ODT</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291797</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312719</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312727</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312735</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312743</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-risperidone</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312751</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372622</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372630</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372649</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372657</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372665</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-risperidone</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372673</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280906</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280914</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280922</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280930</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280949</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02280957</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-30</started-marketing-on>
      <ended-marketing-on>2012-06-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328305</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328321</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328348</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328364</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328372</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264757</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264765</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264773</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264781</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264803</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-risperidone</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264811</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2015-10-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-705</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2017-11-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2017-11-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1408</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2017-11-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2017-11-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-519</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025299</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025280</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-06</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230455</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-28</started-marketing-on>
      <ended-marketing-on>2009-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025310</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-294</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-07</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240552</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA020588</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-491</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02298465</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>12.5 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02255707</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>25 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02255723</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>37.5 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02255758</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>50 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021346</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021346</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021346</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal Consta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021346</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02268086</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-20</started-marketing-on>
      <ended-marketing-on>2016-11-29</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02268094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-20</started-marketing-on>
      <ended-marketing-on>2016-09-28</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247705</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-27</started-marketing-on>
      <ended-marketing-on>2017-02-02</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247706</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-27</started-marketing-on>
      <ended-marketing-on>2017-01-04</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on>2018-03-23</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247704</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-27</started-marketing-on>
      <ended-marketing-on>2017-05-26</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-335</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal M-tab</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperdal Oral Solution</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236950</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA020588</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-12</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-229</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Citron Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>57237-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-18</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-432</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2780</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0978</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0979</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54838-563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202386</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6358</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-642</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-264</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-558</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-559</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-560</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-561</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on>2017-03-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-562</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5881</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on>2018-03-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on>2017-03-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>16252-563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-05</started-marketing-on>
      <ended-marketing-on>2017-02-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077860</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on>2017-03-15</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0876</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-214</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-9424</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-03</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079158</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-215</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-216</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-217</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2018-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amneal Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65162-673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091384</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2018-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code>58165-033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1414</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2018-02-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091384</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6243</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-642</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-0317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078909</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-342</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on>2017-05-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on>2017-05-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0909</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077328</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on>2017-05-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077328</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-11</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-13</started-marketing-on>
      <ended-marketing-on>2018-03-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077328</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-547</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-19</started-marketing-on>
      <ended-marketing-on>2018-03-16</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0574</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-666</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-667</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-668</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343711</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65841-670</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Hikma Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>59115-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078740</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343738</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343746</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2018-02-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343754</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343762</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343770</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Doh Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Gen Source Rx</labeller>
      <ndc-id/>
      <ndc-product-code>52343-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0364</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Msm Repackaging</labeller>
      <ndc-id/>
      <ndc-product-code>42495-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6244</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6245</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-633</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-13</started-marketing-on>
      <ended-marketing-on>2017-01-14</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078464</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-634</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-13</started-marketing-on>
      <ended-marketing-on>2017-01-14</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078464</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2962</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-21</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-13</started-marketing-on>
      <ended-marketing-on>2017-01-14</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078464</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-13</started-marketing-on>
      <ended-marketing-on>2017-01-14</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078464</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-13</started-marketing-on>
      <ended-marketing-on>2017-01-14</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078464</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurobindo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>65862-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-15</started-marketing-on>
      <ended-marketing-on>2017-07-06</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078452</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-06</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078269</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0624</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078871</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>West Ward Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076904</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>55648-692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078744</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090839</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-271</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-272</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Tris Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27808-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-12</started-marketing-on>
      <ended-marketing-on>2016-12-09</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079059</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-273</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Zydus Pharmaceuticals Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-698</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-08</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-526</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079059</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-236</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2138</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-271</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-12</started-marketing-on>
      <ended-marketing-on>2017-04-27</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-849</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-234</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-22</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-14</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2017-11-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-236</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2017-11-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2017-11-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-15</started-marketing-on>
      <ended-marketing-on>2017-08-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on>2017-08-02</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-28</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3479</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-516</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-13</started-marketing-on>
      <ended-marketing-on>2017-08-03</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-642</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-643</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-392</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-644</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-645</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-649</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-01</started-marketing-on>
      <ended-marketing-on>2017-02-14</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303485</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077328</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303493</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077328</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-653</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303507</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-654</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303515</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303523</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303531</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-657</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Heritage</labeller>
      <ndc-id/>
      <ndc-product-code>23155-317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078909</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-256</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-619</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-01</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Nu Care Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-643</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078474</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-644</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078474</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078909</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-01</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-05</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-13</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5684</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-13</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5393</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-5689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2016-08-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on>2016-04-05</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA072688</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078744</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-345</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-035</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091537</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5684</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356902</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356910</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-038</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091384</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356929</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-5689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on>2017-06-22</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356937</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-757</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-08</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076879</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0784</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Mc Kesson Contract Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>76237-269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on>2018-03-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-766</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1349</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090347</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-529</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-29</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356880</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02356899</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2672</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>State of Florida DOH Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-0310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2588</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0081</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078040</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-949</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077542</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077953</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-950</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077542</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077542</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-591</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-592</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-593</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020272</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone - 0.25</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296756</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone - 0.5</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296764</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone - 1</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296772</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone - 2</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296780</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone - 3</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296799</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone - 4</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296802</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-29</started-marketing-on>
      <ended-marketing-on>2008-07-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone M-TAB</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone M-TAB</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone M-TAB</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone M-TAB</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on>2017-11-04</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone M-TAB</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-02</started-marketing-on>
      <ended-marketing-on>2017-11-04</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332051</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332078</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332086</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332108</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Risperidone Tablets</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332116</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283565</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283573</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283581</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283603</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283611</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-risperidone</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283638</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279495</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2008-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279509</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on>2008-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303655</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303663</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279800</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279819</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279827</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279835</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Risperidone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02292807</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-08</started-marketing-on>
      <ended-marketing-on>2008-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264196</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264218</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264226</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282690</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-risperidone</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02264188</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Risperdal</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Risperidal M-Tab</name>
      <company>Janssen</company>
    </international-brand>
    <international-brand>
      <name>Risperin</name>
      <company>Gador</company>
    </international-brand>
    <international-brand>
      <name>Rispolept</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Rispolin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Sequinan</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Oral Solution</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mar-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ran-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 0.25</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 0.5</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 1</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 2</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 3</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone - 4</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ava-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone Tablets</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Nu-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ag-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal Consta</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone M-TAB</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone M-TAB</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone M-TAB</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone M-TAB</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone M-TAB</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Ipg-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mint-risperidon</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Q-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal M-tab</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Riva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Dom-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Act Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-risperidone ODT</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Teva-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperdal</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
    <mixture>
      <name>Risperidone</name>
      <ingredients>Risperidone</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Advanced Pharmaceutical Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Apotex Inc.</name>
      <url>http://www.apotex.com</url>
    </packager>
    <packager>
      <name>Apotheca Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Atlantic Biologicals Corporation</name>
      <url>http://www.atlanticbiologicals.com</url>
    </packager>
    <packager>
      <name>Aurobindo Pharma Ltd.</name>
      <url>http://www.aurobindo.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Cadila Healthcare Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Cobalt Pharmaceuticals Inc.</name>
      <url>http://www.cobaltpharma.com</url>
    </packager>
    <packager>
      <name>Comprehensive Consultant Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Core Pharmaceuticals</name>
      <url>http://www.corepharma.com</url>
    </packager>
    <packager>
      <name>Dept Health Central Pharmacy</name>
      <url/>
    </packager>
    <packager>
      <name>DispenseXpress Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Doctor Reddys Laboratories Ltd.</name>
      <url>http://www.drreddys.com</url>
    </packager>
    <packager>
      <name>Greenstone LLC</name>
      <url>http://www.greenstonellc.com</url>
    </packager>
    <packager>
      <name>Hikma Pharmaceuticals</name>
      <url>http://www.hikma.com</url>
    </packager>
    <packager>
      <name>Janssen-Ortho Inc.</name>
      <url>http://www.janssen-ortho.com</url>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Neuman Distributors Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Nutritional Research Association Inc.</name>
      <url>http://www.nrfeeds.com</url>
    </packager>
    <packager>
      <name>Ortho Mcneil Janssen Pharmaceutical Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>Patriot Pharmaceuticals</name>
      <url>http://www.patriotpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Physician Partners Ltd.</name>
      <url>http://www.pplpho.org</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Pliva Inc.</name>
      <url>http://www.pliva.com</url>
    </packager>
    <packager>
      <name>Prepak Systems Inc.</name>
      <url>http://www.prepaksys.com</url>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Quality Care</name>
      <url/>
    </packager>
    <packager>
      <name>Ratiopharm Inc.</name>
      <url>http://www.ratiopharm.ca</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Roxane Labs</name>
      <url>http://www.roxane.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Sun Pharmaceutical Industries Ltd.</name>
      <url>http://www.sunpharma.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Torrent Pharmaceuticals</name>
      <url>http://www.torrentpharma.com</url>
    </packager>
    <packager>
      <name>UDL Laboratories</name>
      <url>http://www.udllabs.com</url>
    </packager>
    <packager>
      <name>Va Cmop Dallas</name>
      <url/>
    </packager>
    <packager>
      <name>Vangard Labs Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Vintage Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>West-Ward Pharmaceuticals</name>
      <url>http://www.west-ward.com</url>
    </packager>
    <packager>
      <name>Wockhardt Ltd.</name>
      <url>http://www.wockhardtin.com</url>
    </packager>
    <packager>
      <name>Zydus Pharmaceuticals</name>
      <url>http://www.zydususa.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Ortho mcneil janssen pharmaceuticals inc</manufacturer>
    <manufacturer generic="false" url="">Ortho mcneil janssen pharmaceutical inc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc richmond hill</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Dr reddys laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Precision dose inc</manufacturer>
    <manufacturer generic="true" url="">Roxane laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Wockhardt ltd</manufacturer>
    <manufacturer generic="true" url="">Par pharmaceutical inc</manufacturer>
    <manufacturer generic="true" url="">Ranbaxy laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Zydus pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Actavis totowa llc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc</manufacturer>
    <manufacturer generic="true" url="">Cadista pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Mylan pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Pliva hrvatska doo</manufacturer>
    <manufacturer generic="true" url="">Ratiopharm</manufacturer>
    <manufacturer generic="true" url="">Synthon pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Torrent pharmaceuticals ltd</manufacturer>
    <manufacturer generic="true" url="">Vintage pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
    <manufacturer generic="true" url="">West ward pharmaceuticals corp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Risperdal M-Tab 1 mg Disintegrating Tablet</description>
      <cost currency="USD">1.16</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 2 mg Tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 0.25 mg tablet</description>
      <cost currency="USD">1.88</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 3 mg Tablet</description>
      <cost currency="USD">1.9</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal M-Tab 2 mg Disintegrating Tablet</description>
      <cost currency="USD">2.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 4 mg Tablet</description>
      <cost currency="USD">2.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 0.5 mg tablet</description>
      <cost currency="USD">3.03</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 1 mg tablet</description>
      <cost currency="USD">3.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal M-Tab 3 mg Disintegrating Tablet</description>
      <cost currency="USD">3.44</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 0.5 mg tablet</description>
      <cost currency="USD">3.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 0.25 mg odt</description>
      <cost currency="USD">4.48</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 0.25 mg tablet</description>
      <cost currency="USD">4.56</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal M-Tab 4 mg Disintegrating Tablet</description>
      <cost currency="USD">4.6</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone m-tab 0.5 mg odt</description>
      <cost currency="USD">4.71</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone M-TAB 0.5 mg Dispersible Tablet</description>
      <cost currency="USD">4.9</cost>
      <unit>dispersible tablet</unit>
    </price>
    <price>
      <description>Risperidone m-tab 1 mg odt</description>
      <cost currency="USD">5.5</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 2 mg tablet</description>
      <cost currency="USD">5.59</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal m-tab 0.5 mg odt</description>
      <cost currency="USD">5.76</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 1 mg tablet</description>
      <cost currency="USD">6.12</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 3 mg tablet</description>
      <cost currency="USD">6.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal m-tab 1 mg odt</description>
      <cost currency="USD">6.73</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 2 mg tablet</description>
      <cost currency="USD">6.94</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone m-tab 2 mg odt</description>
      <cost currency="USD">8.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone 4 mg tablet</description>
      <cost currency="USD">9.0</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal m-tab 2 mg odt</description>
      <cost currency="USD">10.95</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone m-tab 3 mg odt</description>
      <cost currency="USD">11.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 3 mg tablet</description>
      <cost currency="USD">11.45</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal m-tab 3 mg odt</description>
      <cost currency="USD">13.81</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperidone m-tab 4 mg odt</description>
      <cost currency="USD">15.16</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal 4 mg tablet</description>
      <cost currency="USD">16.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal m-tab 4 mg odt</description>
      <cost currency="USD">18.55</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal consta 12.5 mg syr</description>
      <cost currency="USD">148.22</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Risperidone 1 mg/ml Solution 30ml Bottle</description>
      <cost currency="USD">158.66</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Risperdal M-TAB 28 0.5 mg Dispersible Tablet Bottle</description>
      <cost currency="USD">167.82</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Risperdal M-TAB 28 1 mg Dispersible Tablet Box</description>
      <cost currency="USD">196.08</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Risperdal 1 mg/ml Solution 30ml Bottle</description>
      <cost currency="USD">204.42</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Risperdal consta 25 mg syr</description>
      <cost currency="USD">296.46</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Risperdal consta 37.5 mg syr</description>
      <cost currency="USD">444.68</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Risperdal consta 50 mg syr</description>
      <cost currency="USD">592.93</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Apo-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 0.25 mg Tablet</description>
      <cost currency="USD">0.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 0.5 mg Tablet</description>
      <cost currency="USD">0.46</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Co Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Mylan-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Phl-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ran-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rbx-Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Risperidone 1 mg Tablet</description>
      <cost currency="USD">0.63</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Risperdal M-Tab 0.5 mg Disintegrating Tablet</description>
      <cost currency="USD">0.84</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alpha1 Antagonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alpha2 Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antipsychotic Agents</category>
      <mesh-id>D014150</mesh-id>
    </category>
    <category>
      <category>Antipsychotic Agents (Second Generation [Atypical])</category>
      <mesh-id/>
    </category>
    <category>
      <category>Atypical Antipsychotic</category>
      <mesh-id/>
    </category>
    <category>
      <category>Atypical Antipsychotics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Depressants</category>
      <mesh-id>D002492</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors</category>
      <mesh-id>D065690</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A7 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Dopamine Agents</category>
      <mesh-id>D015259</mesh-id>
    </category>
    <category>
      <category>Dopamine Antagonists</category>
      <mesh-id>D018492</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds</category>
      <mesh-id>D006571</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, 1-Ring</category>
      <mesh-id>D006573</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Psycholeptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychotropic Drugs</category>
      <mesh-id>D011619</mesh-id>
    </category>
    <category>
      <category>Pyrimidines</category>
      <mesh-id>D011743</mesh-id>
    </category>
    <category>
      <category>Pyrimidinones</category>
      <mesh-id>D011744</mesh-id>
    </category>
    <category>
      <category>QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome</category>
      <mesh-id>D020230</mesh-id>
    </category>
    <category>
      <category>Serotonin Agents</category>
      <mesh-id>D018490</mesh-id>
    </category>
    <category>
      <category>Serotonin Antagonists</category>
      <mesh-id>D012702</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Tranquilizing Agents</category>
      <mesh-id>D014149</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.50 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>0.5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.0 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2.0 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>3.0 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>4.0 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>3 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>4 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.25 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>3 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>4 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>12.5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>25 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>37.5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>.25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N05AX08">
      <level code="N05AX">Other antipsychotics</level>
      <level code="N05A">ANTIPSYCHOTICS</level>
      <level code="N05">PSYCHOLEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:16.08.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00734.pdf?1265922811</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00734.pdf?1517857147</msds>
  <patents>
    <patent>
      <number>6110921</number>
      <country>United States</country>
      <approved>1993-11-19</approved>
      <expires>2013-11-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2406536</number>
      <country>Canada</country>
      <approved>2009-12-22</approved>
      <expires>2021-04-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2194564</number>
      <country>Canada</country>
      <approved>1998-01-27</approved>
      <expires>2015-07-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6667061</number>
      <country>United States</country>
      <approved>2000-11-25</approved>
      <expires>2020-11-25</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>5792477</number>
      <country>United States</country>
      <approved>1997-11-02</approved>
      <expires>2017-11-02</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>5916598</number>
      <country>United States</country>
      <approved>1997-11-02</approved>
      <expires>2017-11-02</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6379703</number>
      <country>United States</country>
      <approved>1999-06-30</approved>
      <expires>2019-06-30</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6403114</number>
      <country>United States</country>
      <approved>1997-11-02</approved>
      <expires>2017-11-02</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6596316</number>
      <country>United States</country>
      <approved>1999-06-30</approved>
      <expires>2019-06-30</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6194006</number>
      <country>United States</country>
      <approved>1999-06-30</approved>
      <expires>2019-06-30</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6224905</number>
      <country>United States</country>
      <approved>1997-12-10</approved>
      <expires>2017-12-10</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>Esmirtazapine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Amantadine can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12478</drugbank-id>
      <name>Piribedil</name>
      <description>The therapeutic efficacy of Piribedil can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>Risperidone may increase the arrhythmogenic activities of Mequitazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Risperidone can be increased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Risperidone can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Risperidone can be increased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Risperidone can be increased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Risperidone can be increased when combined with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Risperidone can be increased when combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Risperidone can be increased when combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Risperidone can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Risperidone can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The metabolism of Risperidone can be increased when combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Voriconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Risperidone may increase the QTc-prolonging activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>Risperidone may increase the QTc-prolonging activities of Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>Risperidone may increase the QTc-prolonging activities of Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Risperidone may increase the QTc-prolonging activities of Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Risperidone may increase the QTc-prolonging activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Risperidone may increase the QTc-prolonging activities of Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>Risperidone may increase the QTc-prolonging activities of Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Risperidone may increase the QTc-prolonging activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>Risperidone may increase the QTc-prolonging activities of Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>Risperidone may increase the QTc-prolonging activities of Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>Risperidone may increase the QTc-prolonging activities of Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Risperidone can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Risperidone can be decreased when combined with Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may decrease the antihypertensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The therapeutic efficacy of Risperidone can be increased when used in combination with Isocarboxazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Risperidone can be increased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Risperidone may increase the sedative activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Risperidone may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Risperidone may increase the sedative activities of Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Fosaprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Risperidone may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The risk or severity of adverse effects can be increased when Rufinamide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08933</drugbank-id>
      <name>Luliconazole</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Luliconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The therapeutic efficacy of Risperidone can be decreased when used in combination with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Risperidone can be increased when used in combination with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>Risperidone may increase the QTc-prolonging activities of Perflutren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Risperidone may increase the QTc-prolonging activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Risperidone may increase the QTc-prolonging activities of Gadobenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>Risperidone may increase the QTc-prolonging activities of Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>Risperidone may increase the QTc-prolonging activities of Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>Risperidone may increase the QTc-prolonging activities of Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>Risperidone may increase the QTc-prolonging activities of Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Risperidone may increase the QTc-prolonging activities of Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>Risperidone may increase the QTc-prolonging activities of Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>Risperidone may increase the QTc-prolonging activities of Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Risperidone may increase the QTc-prolonging activities of Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09097</drugbank-id>
      <name>Quinagolide</name>
      <description>The therapeutic efficacy of Quinagolide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>Lithium may increase the neurotoxic activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The metabolism of Risperidone can be decreased when combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The metabolism of Risperidone can be decreased when combined with Sildenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00257</drugbank-id>
      <name>Clotrimazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Clotrimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Atomoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The metabolism of Risperidone can be decreased when combined with Doxycycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The metabolism of Risperidone can be decreased when combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The metabolism of Risperidone can be decreased when combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The metabolism of Risperidone can be decreased when combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The metabolism of Risperidone can be decreased when combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The metabolism of Risperidone can be decreased when combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The metabolism of Risperidone can be decreased when combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The metabolism of Risperidone can be decreased when combined with Cholecalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Risperidone can be decreased when combined with Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The metabolism of Risperidone can be decreased when combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The metabolism of Risperidone can be decreased when combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The metabolism of Risperidone can be decreased when combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of adverse effects can be increased when Codeine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Meprobamate is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluphenazine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepate</name>
      <description>The risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The risk or severity of adverse effects can be increased when Midazolam is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The risk or severity of adverse effects can be increased when Flurazepam is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Zopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Estazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>Gamma Hydroxybutyric Acid</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Gamma Hydroxybutyric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Baclofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Meclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Clonazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Vigabatrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Levocabastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Cyclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Difenoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ezogabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Levocetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin Enacarbil</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin Enacarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tasimelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethchlorvynol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Enflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Etomidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00298</drugbank-id>
      <name>Dapiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dapiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Cinchocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dyclonine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00750</drugbank-id>
      <name>Prilocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Halazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00807</drugbank-id>
      <name>Proparacaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00892</drugbank-id>
      <name>Oxybuprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Oxybuprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01086</drugbank-id>
      <name>Benzocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Benzocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chlormezanone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levomethadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butethal</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Butethal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methadyl Acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Glutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Heroin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Heroin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01525</drugbank-id>
      <name>Ecgonine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ecgonine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Drotebanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02665</drugbank-id>
      <name>(1R,2S)-2-Phenylcyclopropanaminium</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Trans-2-Phenylcyclopropylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04688</drugbank-id>
      <name>Methylecgonine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methylecgonine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Ethyl carbamate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methaqualone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tetrodotoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05424</drugbank-id>
      <name>Canertinib</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Canertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>clomethiazole</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with clomethiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Adipiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06671</drugbank-id>
      <name>PSD502</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with PSD502.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fospropofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Etifoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08987</drugbank-id>
      <name>Etidocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Etidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Articaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Brotizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09085</drugbank-id>
      <name>Tetracaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tetracaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09342</drugbank-id>
      <name>Propoxycaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Propoxycaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09345</drugbank-id>
      <name>Pramocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Pramocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11148</drugbank-id>
      <name>Butamben</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Butamben.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11304</drugbank-id>
      <name>Phenoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Phenoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Alfaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11502</drugbank-id>
      <name>Butacaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Butacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tiletamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine methanesulfonate</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tricaine methanesulfonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Zolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Allopregnanolone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Allopregnanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Eltanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12532</drugbank-id>
      <name>Oxethazaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Oxethazaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Indiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tandospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12972</drugbank-id>
      <name>Sepranolone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Sepranolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13116</drugbank-id>
      <name>Norflurane</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Norflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Propanidid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Proxibarbal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13259</drugbank-id>
      <name>Ethyl chloride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Bromisoval.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Xenon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Mebicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13683</drugbank-id>
      <name>Quinisocaine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Quinisocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Vinyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Lormetazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Cyclopropane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The therapeutic efficacy of Risperidone can be decreased when used in combination with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin Human</name>
      <description>The therapeutic efficacy of Insulin Human can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin Lispro</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin Pork</name>
      <description>The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The therapeutic efficacy of Troglitazone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00419</drugbank-id>
      <name>Miglustat</name>
      <description>The therapeutic efficacy of Miglustat can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The therapeutic efficacy of Repaglinide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The therapeutic efficacy of Exenatide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The therapeutic efficacy of Pramlintide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The therapeutic efficacy of Allicin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The therapeutic efficacy of Gusperimus can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of adverse effects can be increased when Vilazodone is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Linezolid is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Sumatriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Rizatriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Frovatriptan is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid Phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The serum concentration of Rilpivirine can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The metabolism of Risperidone can be decreased when combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The metabolism of Risperidone can be decreased when combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Risperidone can be decreased when combined with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The metabolism of Risperidone can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The metabolism of Risperidone can be decreased when combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The metabolism of Risperidone can be decreased when combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The metabolism of Risperidone can be decreased when combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The metabolism of Risperidone can be decreased when combined with Etoperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The metabolism of Risperidone can be decreased when combined with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>Risperidone may decrease the stimulatory activities of Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>Risperidone may decrease the stimulatory activities of Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>Risperidone may decrease the stimulatory activities of Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>Risperidone may decrease the stimulatory activities of Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>Risperidone may decrease the stimulatory activities of MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>3,4-Methylenedioxyamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>Risperidone may decrease the stimulatory activities of Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Methamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Methamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09352</drugbank-id>
      <name>Hydroxyamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of Hydroxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>Risperidone may decrease the stimulatory activities of Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>Risperidone may decrease the stimulatory activities of Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>Risperidone may decrease the stimulatory activities of Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>Risperidone may decrease the stimulatory activities of Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>Risperidone may decrease the stimulatory activities of Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>Risperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>Amifostine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Amiodarone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>Apomorphine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Arotinolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Arsenic trioxide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>Barnidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Bepridil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>Bortezomib may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Bromocriptine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>Bupivacaine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>Carbetocin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>Cilnidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Clofarabine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Clozapine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Desflurane may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Efonidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Enalaprilat may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Fenoldopam may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>Fimasartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>Halothane may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Imidapril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>Indoramin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Isoflurane may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Lacidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Lercanidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Levobupivacaine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>Levodopa may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>Levosimendan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Lofexidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>Morphine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>Moxonidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Nilvadipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Nitrendipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Nitric Oxide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>Obinutuzumab may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Oxprenolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>Paclitaxel may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>Phenoxybenzamine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Phentolamine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Pipamperone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>Propofol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>Remifentanil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Sacubitril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>Nitrous acid may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Streptokinase may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>Sufentanil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Tamsulosin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>Tolazoline may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Tolcapone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>Tretinoin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>Valsartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Ramipril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Esmolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Betaxolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Olmesartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Chlorthalidone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Atenolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Diltiazem may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>Minoxidil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Timolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Amlodipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Nimodipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Nisoldipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Spironolactone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>Prazosin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Sotalol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Fosinopril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Trandolapril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>Carteolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Metolazone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Benazepril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Propranolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>Clonidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Enalapril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>Doxazosin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Labetalol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Bisoprolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Nicardipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Dexmedetomidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Mecamylamine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>Losartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Moexipril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Tizanidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Eplerenone may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Lisinopril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>Nitroglycerin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Mannitol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Perindopril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>Candesartan cilexetil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>Eprosartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Quinapril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide Dinitrate</name>
      <description>Isosorbide Dinitrate may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00964</drugbank-id>
      <name>Apraclonidine</name>
      <description>Apraclonidine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Telmisartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Methyldopa may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Hydrochlorothiazide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Guanfacine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide Mononitrate</name>
      <description>Isosorbide Mononitrate may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Felodipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>Irbesartan may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>Papaverine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Nifedipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Carvedilol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>Bretylium may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>Terazosin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Acebutolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Captopril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Nadolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01210</drugbank-id>
      <name>Levobunolol</name>
      <description>Levobunolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01214</drugbank-id>
      <name>Metipranolol</name>
      <description>Metipranolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Quetiapine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Hydralazine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Cilazapril may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Penbutolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>Amyl Nitrite may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Nebivolol may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>Nesiritide may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Clevidipine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>Azilsartan medoxomil may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Riociguat may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>Isoxsuprine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Aliskiren may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Empagliflozin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>Dinutuximab may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Aprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The serum concentration of Thioridazine can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Pravastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Lovastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The serum concentration of Fluvastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The serum concentration of Rosuvastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Pitavastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The serum concentration of Mevastatin can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The risk or severity of adverse effects can be increased when Methysergide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The risk or severity of adverse effects can be increased when Lisuride is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Ergotamine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>The risk or severity of adverse effects can be increased when Nicergoline is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The risk or severity of adverse effects can be increased when Ergonovine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The risk or severity of adverse effects can be increased when Methylergometrine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The risk or severity of adverse effects can be increased when Pergolide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic Acid Diethylamide</name>
      <description>The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>The risk or severity of adverse effects can be increased when Terguride is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>The risk or severity of adverse effects can be increased when Metergoline is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06704</drugbank-id>
      <name>Iobenguane</name>
      <description>The therapeutic efficacy of Iobenguane can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Risperidone may increase the antipsychotic activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Risperidone may increase the antipsychotic activities of Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The serum concentration of Ibrutinib can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Tolvaptan can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Dapoxetine is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic Acid</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Fusidic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Lorpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The serum concentration of Conivaptan can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Pitolisant can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Risperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02261</drugbank-id>
      <name>Platelet Activating Factor</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Risperidone may increase the atrioventricular blocking (AV block) activities of Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>L-Tryptophan</name>
      <description>L-Tryptophan may increase the serotonergic activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of adverse effects can be increased when Azosemide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Verapamil.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.27</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.71e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>risperidone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>410.4845</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>410.211804333</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C23H27FN4O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RAPZEAPATHNIPO-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>61.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>114.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>45.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>2.33 mg/mL</value>
      <source>[FDA]</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>170</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>442</value>
      <source>[FDA]</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>723</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>8871</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5073</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505850</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00426</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4895</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50001885</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451257</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000003</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>96</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>96</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Risperidone</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL85</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/risperid.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=ris1382.html&amp;contentName=Risperdal&amp;contentId=667</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/risperidone.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00734</drugbank-id>
        <name>Risperidone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00323</drugbank-id>
        <name>9-hydroxyrisperidone</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002363</drugbank-id>
          <name>Cytochrome P450 2D6</name>
          <uniprot-id>P10635</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003612</drugbank-id>
          <name>Cytochrome P450 3A7</name>
          <uniprot-id>P24462</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000451</id>
      <name>5-hydroxytryptamine receptor 2A</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>15992090</pubmed-id>
            <citation>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>17316700</pubmed-id>
            <citation>Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P28223" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 2A</name>
    <general-function>Virus receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.</specific-function>
    <gene-name>HTR2A</gene-name>
    <locus>13q14-q21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>76-99
111-132
149-171
192-215
234-254
325-346
363-384</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.72</theoretical-pi>
    <molecular-weight>52602.58</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5293</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>S42168</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>36431</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28223</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-2</synonym>
      <synonym>HTR2</synonym>
      <synonym>Serotonin receptor 2A</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000899|5-hydroxytryptamine receptor 2A
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC
LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD
MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP
IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF
VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH
REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA
LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020465|5-hydroxytryptamine receptor 2A (HTR2A)
ATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAA
TTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAAGCTAACACTTCT
GATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGC
CTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTG
ACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCC
CTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTTGCCATAGCTGAT
ATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTGTATGGGTACCGG
TGGCCTCTGCCGAGCAAGCTTTGTGCAGTCTGGATTTACCTGGACGTGCTCTTCTCCACG
GCCTCCATCATGCACCTCTGCGCCATCTCGCTGGACCGCTACGTCGCCATCCAGAATCCC
ATCCACCACAGCCGCTTCAACTCCAGAACTAAGGCATTTCTGAAAATCATTGCTGTTTGG
ACCATATCAGTAGGTATATCCATGCCAATACCAGTCTTTGGGCTACAGGACGATTCGAAG
GTCTTTAAGGAGGGGAGTTGCTTACTCGCCGATGATAACTTTGTCCTGATCGGCTCTTTT
GTGTCATTTTTCATTCCCTTAACCATCATGGTGATCACCTACTTTCTAACTATCAAGTCA
CTCCAGAAAGAAGCTACTTTGTGTGTAAGTGATCTTGGCACACGGGCCAAATTAGCTTCT
TTCAGCTTCCTCCCTCAGAGTTCTTTGTCTTCAGAAAAGCTCTTCCAGCGGTCGATCCAT
AGGGAGCCAGGGTCCTACACAGGCAGGAGGACTATGCAGTCCATCAGCAATGAGCAAAAG
GCATGCAAGGTGCTGGGCATCGTCTTCTTCCTGTTTGTGGTGATGTGGTGCCCTTTCTTC
ATCACAAACATCATGGCCGTCATCTGCAAAGAGTCCTGCAATGAGGATGTCATTGGGGCC
CTGCTCAATGTGTTTGTTTGGATCGGTTATCTCTCTTCAGCAGTCAACCCACTAGTCTAC
ACACTGTTCAACAAGACCTATAGGTCAGCCTTTTCACGGTATATTCAGTGTCAGTACAAG
GAAAACAAAAAACCATTGCAGTTAATTTTAGTGAACACAATACCGGCTTTGGCCTACAAG
TCTAGCCAACTTCAAATGGGACAAAAAAAGAATTCAAAGCAAGATGCCAAGACAACAGAT
AATGACTGCTCAATGGTTGCTCTAGGAAAGCAGCATTCTGAAGAGGCTTCTAAAGACAAT
AGCGACGGAGTGAATGAAAAGGTGAGCTGTGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic shaft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bounded vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell body fiber</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>virus receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of mechanical stimulus involved in sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urinary bladder smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to cytoskeleton</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of temperature stimulus involved in sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>artery smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>temperature homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycolytic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000756</id>
      <name>D(2) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17059881</pubmed-id>
            <citation>Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E: Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res. 2006 Dec 1;148(2-3):175-83. Epub 2006 Oct 23.</citation>
          </article>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>15140279</pubmed-id>
            <citation>Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004 Dec;7(4):461-70. Epub 2004 May 12.</citation>
          </article>
          <article>
            <pubmed-id>16730699</pubmed-id>
            <citation>Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11.</citation>
          </article>
          <article>
            <pubmed-id>16513859</pubmed-id>
            <citation>Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14416" source="Swiss-Prot">
    <name>D(2) dopamine receptor</name>
    <general-function>Potassium channel regulator activity</general-function>
    <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.</specific-function>
    <gene-name>DRD2</gene-name>
    <locus>11q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>38-60
71-93
109-130
152-172
189-213
374-395
410-431</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.85</theoretical-pi>
    <molecular-weight>50618.91</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3023</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M30625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>215</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>215</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14416</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Dopamine D2 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001508|D(2) dopamine receptor
MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVS
REKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTA
SILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQN
ECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPL
KGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPP
SHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSR
RKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSA
VNPIIYTTFNIEFRKAFLKILHC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021274|D(2) dopamine receptor (DRD2)
ATGGATCCACTGAATCTGTCCTGGTATGATGATGATCTGGAGAGGCAGAACTGGAGCCGG
CCCTTCAACGGGTCAGACGGGAAGGCGGACAGACCCCACTACAACTACTATGCCACACTG
CTCACCCTGCTCATCGCTGTCATCGTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC
CGCGAGAAGGCGCTGCAGACCACCACCAACTACCTGATCGTCAGCCTCGCAGTGGCCGAC
CTCCTCGTCGCCACACTGGTCATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTGAGTGG
AAATTCAGCAGGATTCACTGTGACATCTTCGTCACTCTGGACGTCATGATGTGCACGGCG
AGCATCCTGAACTTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCCATGCCCATG
CTGTACAATACGCGCTACAGCTCCAAGCGCCGGGTCACCGTCATGATCTCCATCGTCTGG
GTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC
GAGTGCATCATTGCCAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG
CCCTTCATTGTCACCCTGCTGGTCTACATCAAGATCTACATTGTCCTCCGCAGACGCCGC
AAGCGAGTCAACACCAAACGCAGCAGCCGAGCTTTCAGGGCCCACCTGAGGGCTCCACTA
AAGGGCAACTGTACTCACCCCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT
GGGAGTTTCCCAGTGAACAGGCGGAGAGTGGAGGCTGCCCGGCGAGCCCAGGAGCTGGAG
ATGGAGATGCTCTCCAGCACCAGCCCACCCGAGAGGACCCGGTACAGCCCCATCCCACCC
AGCCACCACCAGCTGACTCTCCCCGACCCGTCCCACCATGGTCTCCACAGCACTCCCGAC
AGCCCCGCCAAACCAGAGAAGAATGGGCATGCCAAAGACCACCCCAAGATTGCCAAGATC
TTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTCAAGACCATGAGCCGT
AGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTCGCCATTGTTCTCGGC
GTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGTGAC
TGCAACATCCCGCCTGTCCTGTACAGCGCCTTCACGTGGCTGGGCTATGTCAACAGCGCC
GTGAACCCCATCATCTACACCACCTTCAACATTGAGTTCCGCAAGGCCTTCCTGAAGATC
CTCCACTGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>postsynaptic density</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon terminus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perikaryon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sperm flagellum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>acrosomal vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ciliary membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nonmotile primary cilium</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>potassium channel regulator activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenohypophysis development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synaptic transmission, GABAergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glial cell-derived neurotrophic factor secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nicotine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prepulse inhibition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion involved in locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of long-term neuronal synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of smell</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to toxic substance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>auditory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synapse structural plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of phosphoprotein phosphatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of voltage-gated calcium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching morphogenesis of a nerve</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to light stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cAMP metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>temperature homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex GABAergic interneuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of sodium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of heart rate</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>pigmentation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>grooming behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult walking behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokinesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synapse assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peristalsis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>feeding behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of long-term synaptic potentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>long-term memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>associative learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron-neuron synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of circadian sleep/wake cycle, sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of urine volume</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to axon injury</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>striatum development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to iron ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase activity</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000581</id>
      <name>D(3) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>7520908</pubmed-id>
            <citation>Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.</citation>
          </article>
          <article>
            <pubmed-id>7531353</pubmed-id>
            <citation>Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35462" source="Swiss-Prot">
    <name>D(3) dopamine receptor</name>
    <general-function>G-protein coupled amine receptor activity</general-function>
    <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.</specific-function>
    <gene-name>DRD3</gene-name>
    <locus>3q13.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>33-55
66-88
105-126
150-170
188-212
330-351
367-388</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.07</theoretical-pi>
    <molecular-weight>44224.335</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3024</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U32499</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>927342</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>216</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>216</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35462</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD3_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Dopamine D3 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001159|D(3) dopamine receptor
MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERAL
QTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILN
LCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTV
CSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQ
QTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRK
LSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHV
SPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021269|D(3) dopamine receptor (DRD3)
ATGGCATCTCTGAGCCAGCTGAGTGGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC
ACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC
CTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG
CAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC
TTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC
ATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT
CTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT
GGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG
GCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC
TGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC
TTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG
AAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA
CAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG
GACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG
AAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA
CTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG
CCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC
TGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG
TCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT
GTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>apical part of cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell projection</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled amine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>musculoskeletal movement, spinal reflex action</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood volume by renin-angiotensin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of oligodendrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of sodium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion involved in locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>social behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of circadian sleep/wake cycle, sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokinesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cAMP metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prepulse inhibition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gastric emptying</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian regulation of gene expression</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000389</id>
      <name>D(4) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>7520908</pubmed-id>
            <citation>Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.</citation>
          </article>
          <article>
            <pubmed-id>7531353</pubmed-id>
            <citation>Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21917" source="Swiss-Prot">
    <name>D(4) dopamine receptor</name>
    <general-function>Sh3 domain binding</general-function>
    <specific-function>Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).</specific-function>
    <gene-name>DRD4</gene-name>
    <locus>11p15.5</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>38-60
71-93
110-131
152-175
192-213
395-417
427-449</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.37</theoretical-pi>
    <molecular-weight>48359.86</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3025</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L12398</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>291946</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>217</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>217</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P21917</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>D(2C) dopamine receptor</synonym>
      <synonym>Dopamine D4 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000775|D(4) dopamine receptor
MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVA
TERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCT
ASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGR
DPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSG
PGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPGLPPDPCGPDCAPPAPG
LPQDPCGPDCAPPAPGLPRGPCGPDCAPPAPGLPQDPCGPDCAPPAPGLPPDPCGSNCAP
PDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWTPFFVVHITQALC
PACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010271|D(4) dopamine receptor (DRD4)
ATGGGGAACCGCAGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCCGGCCGCG
GGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCGGCGCTGGTGGGG
GGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAACTCGCTCGTGTGCGTGAGCGTGGCC
ACCGAGCGCGCCCTGCAGACGCCCACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGAC
CTCCTCCTCGCTCTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG
TGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTCATGCTGTGCACC
GCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGACAGGTTCGTGGCCGTGGCCGTGCCG
CTGCGCTACAACCGGCAGGGTGGGAGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGG
CTGCTGTCCGCGGCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC
GACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCGTCCGTGTGCTCC
TTCTTCCTACCCTGCCCGCTCATGCTGCTGCTCTACTGGGCCACGTTCCGCGGCCTGCAG
CGCTGGGAGGTGGCACGTCGCGCCAAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGC
CCTGGCCCGCCTTCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC
GACTGTGCGCCCCCCGCGCCCGGCCTTCCCCGGGGTCCCTGCGGCCCCGACTGTGCGCCC
GCCGCGCCCAGCCTCCCCCAGGACCCCTGCGGCCCCGACTGTGCGCCCCCCGCGCCCGGC
CTCCCCCCGGACCCCTGCGGCTCCAACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCG
CTCCCACCCCAGACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG
GAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTGCTGTGCTGGACG
CCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGTCCTGCCTGCTCCGTGCCCCCGCGG
CTGGTCAGCGCCGTCACCTGGCTGGGCTACGTCAACAGCGCCCTCAACCCCGTCATCTAC
ACTGTCTTCAACGCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>terminal bouton</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled amine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>SH3 domain binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>potassium channel regulator activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retina development in camera-type eye</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of excitatory postsynaptic potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of penile erection</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of sodium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of neurotransmitter secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inhibitory postsynaptic potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of voltage-gated calcium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>social behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>olfactory learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to steroid hormone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>photoperiodism</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>short-term memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0000501</id>
      <name>Alpha-1A adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>8925876</pubmed-id>
            <citation>Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73.</citation>
          </article>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>15992090</pubmed-id>
            <citation>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</citation>
          </article>
          <article>
            <pubmed-id>18542932</pubmed-id>
            <citation>Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>7691623</pubmed-id>
            <citation>Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35348" source="Swiss-Prot">
    <name>Alpha-1A adrenergic receptor</name>
    <general-function>Protein heterodimerization activity</general-function>
    <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
    <gene-name>ADRA1A</gene-name>
    <locus>8p21-p11.2</locus>
    <cellular-location>Nucleus membrane</cellular-location>
    <transmembrane-regions>28-51
65-88
100-122
144-167
182-205
274-297
306-329</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.23</theoretical-pi>
    <molecular-weight>51486.005</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:277</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D25235</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>433201</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>22</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>22</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35348</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA1A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA1C</synonym>
      <synonym>Alpha-1A adrenoceptor</synonym>
      <synonym>Alpha-1A adrenoreceptor</synonym>
      <synonym>Alpha-1C adrenergic receptor</synonym>
      <synonym>Alpha-adrenergic receptor 1c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001000|Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A)
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha1-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of action potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hormone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase C signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, GABAergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium ion transport into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of Rho protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cardiac muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0000575</id>
      <name>Alpha-1B adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <pubmed-id>8925876</pubmed-id>
            <citation>Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73.</citation>
          </article>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>15992090</pubmed-id>
            <citation>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>7691623</pubmed-id>
            <citation>Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35368" source="Swiss-Prot">
    <name>Alpha-1B adrenergic receptor</name>
    <general-function>Protein heterodimerization activity</general-function>
    <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
    <gene-name>ADRA1B</gene-name>
    <locus>5q23-q32</locus>
    <cellular-location>Nucleus membrane</cellular-location>
    <transmembrane-regions>46-70
84-105
116-141
162-184
202-224
296-319
327-351</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.79</theoretical-pi>
    <molecular-weight>56835.375</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:278</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA1B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M99589</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>23</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>23</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35368</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA1B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Alpha-1B adrenoceptor</synonym>
      <synonym>Alpha-1B adrenoreceptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010399|Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010400|Alpha-1B adrenergic receptor (ADRA1B)
ATGAATCCCGACCTGGACACCGGCCACAACACATCAGCACCTGCCCACTGGGGAGAGTTG
AAAAATGCCAACTTCACTGGCCCCAACCAGACCTCGAGCAACTCCACACTGCCCCAGCTG
GACATCACCAGGGCCATCTCTGTGGGCCTGGTGCTGGGCGCCTTCATCCTCTTTGCCATC
GTGGGCAACATCCTAGTCATCTTGTCTGTGGCCTGCAACCGGCACCTGCGGACGCCCACC
AACTACTTCATTGTCAACCTGGCCATGGCCGACCTGCTGTTGAGCTTCACCGTCCTGCCC
TTCTCAGCGGCCCTAGAGGTGCTCGGCTACTGGGTGCTGGGGCGGATCTTCTGTGACATC
TGGGCAGCCGTGGATGTCCTGTGCTGCACAGCGTCCATTCTGAGCCTGTGCGCCATCTCC
ATCGATCGCTACATCGGGGTGCGCTACTCTCTGCAGTATCCCACGCTGGTCACCCGGAGG
AAGGCCATCTTGGCGCTGCTCAGTGTCTGGGTCTTGTCCACCGTCATCTCCATCGGGCCT
CTCCTTGGGTGGAAGGAGCCGGCACCCAACGATGACAAGGAGTGCGGGGTCACCGAAGAA
CCCTTCTATGCCCTCTTCTCCTCTCTGGGCTCCTTCTACATCCCTCTGGCGGTCATTCTA
GTCATGTACTGCCGTGTCTATATAGTGGCCAAGAGAACCACCAAGAACCTAGAGGCAGGA
GTCATGAAGGAGATGTCCAACTCCAAGGAGCTGACCCTGAGGATCCATTCCAAGAACTTT
CACGAGGACACCCTTAGCAGTACCAAGGCCAAGGGCCACAACCCCAGGAGTTCCATAGCT
GTCAAACTTTTTAAGTTCTCCAGGGAAAAGAAAGCAGCTAAGACGTTGGGCATTGTGGTC
GGTATGTTCATCTTGTGCTGGCTACCCTTCTTCATCGCTCTACCGCTTGGCTCCTTGTTC
TCCACCCTGAAGCCCCCCGACGCCGTGTTCAAGGTGGTGTTCTGGCTGGGCTACTTCAAC
AGCTGCCTCAACCCCATCATCTACCCATGCTCCAGCAAGGAGTTCAAGCGCGCTTTCGTG
CGCATCCTCGGGTGCCAGTGCCGCGGCCGCGGCCGCCGCCGACGCCGCCGCCGCCGTCGC
CTGGGCGGCTGCGCCTACACCTACCGGCCGTGGACGCGCGGCGGCTCGCTGGAGCGCTCG
CAGTCGCGCAAGGACTCGCTGGACGACAGCGGCAGCTGCCTGAGCGGCAGCCAGCGGACC
CTGCCCTCGGCCTCGCCGAGCCCGGGCTACCTGGGCCGCGGCGCGCCACCGCCAGTCGAG
CTGTGCGCCTTCCCCGAGTGGAAGGCGCCCGGCGCCCTCCTGAGCCTGCCCGCGCCTGAG
CCCCCCGGCCGCCGCGGCCGCCACGACTCGGGCCCGCTCTTCACCTTCAAGCTCCTGACC
GAGCCCGAGAGCCCCGGGACCGACGGCGGCGCCAGCAACGGAGGCTGCGAGGCCGCGGCC
GACGTGGCCAACGGGCAGCCGGGCTTCAAAAGCAACATGCCCCTGGCGCCCGGGCAGTTT
TAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha1-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycogen catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cardiac muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood vessel remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult heart development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of glycogen catabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0000659</id>
      <name>5-hydroxytryptamine receptor 1D</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28221" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1D</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.</specific-function>
    <gene-name>HTR1D</gene-name>
    <locus>1p36.3-p34.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>39-64
76-98
113-134
155-176
195-217
303-326
336-360</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.85</theoretical-pi>
    <molecular-weight>41906.38</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5289</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1D</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M89955</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>177772</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28221</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1D_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1D</synonym>
      <synonym>5-HT-1D-alpha</synonym>
      <synonym>HTR1DA</synonym>
      <synonym>HTRL</synonym>
      <synonym>Serotonin 1D alpha receptor</synonym>
      <synonym>Serotonin receptor 1D</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010458|5-hydroxytryptamine receptor 1D
MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVL
TTILLTRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDIT
CCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAK
AQEEMSDCLVNTSQISYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFT
TAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIKLADSALERKRISAARERKAT
KILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFN
EEFRQAFQKIVPFRKAS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010459|5-hydroxytryptamine receptor 1D (HTR1D)
ATGTCCCCACTGAACCAGTCAGCAGAAGGCCTTCCCCAGGAGGCCTCCAACAGATCCCTG
AATGCCACAGAAACCTCAGAGGCTTGGGATCCCAGGACCCTCCAGGCGCTCAAGATCTCC
CTTGCCGTGGTCCTTTCCGTCATCACACTGGCCACAGTCCTCTCCAATGCCTTTGTACTC
ACCACCATCTTACTCACCAGGAAGCTCCACACCCCTGCCAACTACCTGATTGGCTCCCTG
GCCACCACCGACCTCTTGGTTTCCATCTTGGTAATGCCCATCAGCATCGCCTATACCATC
ACCCACACCTGGAACTTTGGCCAAATCTTGTGTGACATCTGGCTGTCCTCTGACATCACG
TGCTGCACAGCCTCCATCCTGCATCTCTGTGTCATTGCTCTGGACAGGTACTGGGCAATC
ACAGATGCCCTGGAATACAGTAAACGCAGGACGGCTGGCCACGCGGCCACCATGATCGCC
ATTGTCTGGGCCATCTCCATCTGCATCTCCATCCCCCCGCTCTTCTGGCGGCAGGCCAAG
GCCCAGGAGGAGATGTCGGACTGTCTGGTGAACACCTCTCAGATCTCCTACACCATCTAC
TCCACCTGTGGGGCCTTCTACATTCCCTCGGTGTTGCTCATCATCCTATATGGCCGGATC
TACCGGGCTGCCCGGAACCGCATCCTGAATCCACCCTCACTCTATGGGAAGCGCTTCACC
ACGGCCCACCTCATCACAGGCTCTGCCGGGTCCTCGCTCTGCTCGCTCAACTCCAGCCTC
CATGAGGGGCACTCGCACTCGGCTGGCTCCCCTCTCTTTTTCAACCACGTGAAAATCAAG
CTTGCTGACAGTGCCCTGGAACGCAAGAGGATTTCTGCTGCTCGAGAAAGGAAAGCCACT
AAAATCCTGGGCATCATTCTGGGGGCCTTTATCATCTGCTGGCTGCCCTTCTTCGTGGTG
TCTCTGGTCCTCCCCATCTGCCGGGACTCCTGCTGGATCCACCCGGCGCTCTTTGACTTC
TTCACCTGGCTAGGCTATTTAAACTCCCTCATCAATCCAATAATCTACACTGTGTTTAAT
GAAGAGTTTCGGCAAGCTTTTCAGAAAATTGTCCCTTTCCGGAAGGCCTCCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intestine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to toxic substance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0000442</id>
      <name>Histamine H1 receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15992090</pubmed-id>
            <citation>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>9197279</pubmed-id>
            <citation>Schreiber S, Backer MM, Weizman R, Pick CG: Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett. 1997 May 30;228(1):25-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35367" source="Swiss-Prot">
    <name>Histamine H1 receptor</name>
    <general-function>Histamine receptor activity</general-function>
    <specific-function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.</specific-function>
    <gene-name>HRH1</gene-name>
    <locus>3p25</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>30-52
63-83
102-123
144-164
190-210
417-438
451-470</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.58</theoretical-pi>
    <molecular-weight>55783.61</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5182</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HRH1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z34897</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>510296</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35367</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>HRH1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>H1R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016092|Histamine H1 receptor
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016093|Histamine H1 receptor (HRH1)
ATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC
ACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC
ACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT
GTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC
ATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC
CTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC
CTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC
AAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT
CCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT
GAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC
CTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC
TGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG
CCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG
AAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC
AAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC
TACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC
TATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA
CATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA
ACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT
AACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG
TATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC
ATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC
TGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC
TCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG
AGAATTCTGCATATTCGCTCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>histamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>histamine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>modulation of synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inositol trisphosphate biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vascular permeability</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>eosinophil chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inositol phosphate-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0000289</id>
      <name>Alpha-2A adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08913" source="Swiss-Prot">
    <name>Alpha-2A adrenergic receptor</name>
    <general-function>Thioesterase binding</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline &gt; clonidine &gt; epinephrine &gt; norepinephrine &gt; phenylephrine &gt; dopamine &gt; p-synephrine &gt; p-tyramine &gt; serotonin = p-octopamine. For antagonists, the rank order is yohimbine &gt; phentolamine = mianserine &gt; chlorpromazine = spiperone = prazosin &gt; propanolol &gt; alprenolol = pindolol.</specific-function>
    <gene-name>ADRA2A</gene-name>
    <locus>10q24-q26</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>34-59
71-96
107-129
152-172
195-217
375-395
410-429</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>10.2</theoretical-pi>
    <molecular-weight>48956.275</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:281</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M23533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178196</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>25</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>25</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08913</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2R</synonym>
      <synonym>ADRAR</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C10</synonym>
      <synonym>Alpha-2A adrenoceptor</synonym>
      <synonym>Alpha-2A adrenoreceptor</synonym>
      <synonym>Alpha-2AAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021255|Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC
ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG
CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG
GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC
GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG
TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC
GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC
ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC
TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG
CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC
TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT
CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC
ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG
GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG
CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT
CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG
GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG
GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG
CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG
TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC
ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC
TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC
AGGAAGCGGATCGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thioesterase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-1B adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-2C adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heterotrimeric G-protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>norepinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>thermoception</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of lipid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Rho protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hormone stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of uterine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female pregnancy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transmembrane transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion-dependent exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intestinal absorption</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasodilation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of membrane protein ectodomain proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0000572</id>
      <name>Alpha-2B adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P18089" source="Swiss-Prot">
    <name>Alpha-2B adrenergic receptor</name>
    <general-function>Epinephrine binding</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine &gt; norepinephrine &gt; epinephrine = oxymetazoline &gt; dopamine &gt; p-tyramine = phenylephrine &gt; serotonin &gt; p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine &gt; chlorpromazine &gt; phentolamine &gt; mianserine &gt; spiperone &gt; prazosin &gt; alprenolol &gt; propanolol &gt; pindolol.</specific-function>
    <gene-name>ADRA2B</gene-name>
    <locus>2p13-q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>13-38
49-69
87-107
129-149
173-193
370-393
403-423</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.52</theoretical-pi>
    <molecular-weight>49565.8</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:282</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M34041</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178198</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>26</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>26</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P18089</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2L1</synonym>
      <synonym>ADRA2RL1</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C2</synonym>
      <synonym>Alpha-2B adrenoceptor</synonym>
      <synonym>Alpha-2B adrenoreceptor</synonym>
      <synonym>Alpha-2BAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010396|Alpha-2B adrenergic receptor
MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL
VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY
NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS
FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV
ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE
EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL
TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP
VIYTIFNQDFRRAFRRILCRPWTQTAW</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B)
ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC
TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC
CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG
GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC
CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC
GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC
AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC
GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG
CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT
TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA
CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG
CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG
GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG
ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA
GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG
GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC
TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT
GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG
GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT
GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC
TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA
CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC
CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron differentiation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0000342</id>
      <name>Alpha-2C adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15907153</pubmed-id>
            <citation>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.</citation>
          </article>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P18825" source="Swiss-Prot">
    <name>Alpha-2C adrenergic receptor</name>
    <general-function>Protein homodimerization activity</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.</specific-function>
    <gene-name>ADRA2C</gene-name>
    <locus>4p16</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>52-76
89-114
125-147
169-191
208-231
380-407
421-441</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>10.69</theoretical-pi>
    <molecular-weight>49521.585</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:283</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03853</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178194</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>27</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>27</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P18825</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2L2</synonym>
      <synonym>ADRA2RL2</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C4</synonym>
      <synonym>Alpha-2C adrenoceptor</synonym>
      <synonym>Alpha-2C adrenoreceptor</synonym>
      <synonym>Alpha-2CAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000681|Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C)
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC
GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG
TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG
CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG
CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG
CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC
ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC
AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG
TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC
AGGCAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon terminus</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-2A adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female pregnancy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of uterine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0000533</id>
      <name>5-hydroxytryptamine receptor 2C</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
          <article>
            <pubmed-id>7898773</pubmed-id>
            <citation>Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28335" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 2C</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.</specific-function>
    <gene-name>HTR2C</gene-name>
    <locus>Xq24</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>53-78
90-110
128-150
171-193
214-235
312-333
349-371</transmembrane-regions>
    <signal-regions>1-32</signal-regions>
    <theoretical-pi>9.11</theoretical-pi>
    <molecular-weight>51820.705</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5295</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M81778</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>338028</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28335</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1C</synonym>
      <synonym>5-HT-2C</synonym>
      <synonym>5-HT1C</synonym>
      <synonym>5-hydroxytryptamine receptor 1C</synonym>
      <synonym>HTR1C</synonym>
      <synonym>Serotonin receptor 2C</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001064|5-hydroxytryptamine receptor 2C
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C)
ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT
TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC
TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC
GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG
GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG
CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG
CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG
TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT
GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA
ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG
TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC
GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT
CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT
CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT
AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG
CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT
CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC
TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT
TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC
AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA
GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT
GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT
TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>Gq/11-coupled serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of corticotropin-releasing hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>feeding behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cGMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of appetite</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="13">
      <id>BE0000291</id>
      <name>5-hydroxytryptamine receptor 1A</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11132243</pubmed-id>
            <citation>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08908" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1A</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.</specific-function>
    <gene-name>HTR1A</gene-name>
    <locus>5q11.2-q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>37-62
74-98
111-132
153-178
192-217
346-367
379-403</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.05</theoretical-pi>
    <molecular-weight>46106.335</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5286</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M28269</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189928</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08908</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1A</synonym>
      <synonym>ADRB2RL1</synonym>
      <synonym>ADRBRL1</synonym>
      <synonym>G-21</synonym>
      <synonym>Serotonin receptor 1A</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)
ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG
ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT
CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC
ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC
ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC
AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC
ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC
CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT
TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC
CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC
TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA
GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC
CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC
AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG
GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC
TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT
TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG
AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC
TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG
TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC
GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC
CGCCAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exploration behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of serotonin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="14">
      <id>BE0000020</id>
      <name>D(1A) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15992090</pubmed-id>
            <citation>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</citation>
          </article>
          <article>
            <pubmed-id>7520908</pubmed-id>
            <citation>Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21728" source="Swiss-Prot">
    <name>D(1A) dopamine receptor</name>
    <general-function>G-protein coupled amine receptor activity</general-function>
    <specific-function>Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.</specific-function>
    <gene-name>DRD1</gene-name>
    <locus>5q35.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>24-49
61-87
97-119
139-163
193-218
273-299
313-337</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.34</theoretical-pi>
    <molecular-weight>49292.765</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3020</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X55760</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>30397</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>214</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>214</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P21728</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Dopamine D1 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021252|D(1A) dopamine receptor
MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTN
FFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVD
RYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLA
ETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKN
CQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGS
GETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIET
VSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPAL
SVILDYDTDVSLEKIQPITQNGQHPT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021253|D(1A) dopamine receptor (DRD1)
ATGAGGACTCTGAACACCTCTGCCATGGACGGGACTGGGCTGGTGGTGGAGAGGGACTTC
TCTGTTCGTATCCTCACTGCCTGTTTCCTGTCGCTGCTCATCCTGTCCACGCTCCTGGGG
AACACGCTGGTCTGTGCTGCCGTTATCAGGTTCCGACACCTGCGGTCCAAGGTGACCAAC
TTCTTTGTCATCTCCTTGGCTGTGTCAGATCTCTTGGTGGCCGTCCTGGTCATGCCCTGG
AAGGCAGTGGCTGAGATTGCTGGCTTCTGGCCCTTTGGGTCCTTCTGTAACATCTGGGTG
GCCTTTGACATCATGTGCTCCACTGCATCCATCCTCAACCTCTGTGTGATCAGCGTGGAC
AGGTATTGGGCTATCTCCAGCCCTTTCCGGTATGAGAGAAAGATGACCCCCAAGGCAGCC
TTCATCCTGATCAGTGTGGCATGGACCTTGTCTGTACTCATCTCCTTCATCCCAGTGCAG
CTCAGCTGGCACAAGGCAAAACCCACAAGCCCCTCTGATGGAAATGCCACTTCCCTGGCT
GAGACCATAGACAACTGTGACTCCAGCCTCAGCAGGACATATGCCATCTCATCCTCTGTA
ATAAGCTTTTACATCCCTGTGGCCATCATGATTGTCACCTACACCAGGATCTACAGGATT
GCTCAGAAACAAATACGGCGCATTGCGGCCTTGGAGAGGGCAGCAGTCCACGCCAAGAAT
TGCCAGACCACCACAGGTAATGGAAAGCCTGTCGAATGTTCTCAACCGGAAAGTTCTTTT
AAGATGTCCTTCAAAAGAGAAACTAAAGTCCTGAAGACTCTGTCGGTGATCATGGGTGTG
TTTGTGTGCTGTTGGCTACCTTTCTTCATCTTGAACTGCATTTTGCCCTTCTGTGGGTCT
GGGGAGACGCAGCCCTTCTGCATTGATTCCAACACCTTTGACGTGTTTGTGTGGTTTGGG
TGGGCTAATTCATCCTTGAACCCCATCATTTATGCCTTTAATGCTGATTTTCGGAAGGCA
TTTTCAACCCTCTTAGGATGCTACAGACTTTGCCCTGCGACGAATAATGCCATAGAGACG
GTGAGTATCAATAACAATGGGGCCGCGATGTTTTCCAGCCATCATGAGCCACGAGGCTCC
ATCTCCAAGGAGTGCAATCTGGTTTACCTGATCCCACATGCTGTGGGCTCCTCTGAGGAC
CTGAAAAAGGAGGAGGCAGCTGGCATCGCCAGACCCTTGGAGAAGCTGTCCCCAGCCCTA
TCAGTCATATTGGACTATGACACTGACGTCTCTCTGGAGAAGATCCAACCCATCACACAA
AACGGTCAGCACCCAACCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>nonmotile primary cilium</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon terminus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic shaft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine head</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine neck</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ciliary membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gs</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled amine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of long-term neuronal synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensitization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prepulse inhibition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>astrocyte development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>striatum development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nicotine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>temperature homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to antidepressant</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult walking behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maternal behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose import</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>social behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>conditioned taste aversion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex GABAergic interneuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuronal action potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasodilation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dentate gyrus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmission of nerve impulse</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>habituation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to insulin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synapse assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of long-term synaptic potentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to catecholamine stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of feeding behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to retinoic acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peristalsis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amino acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to food</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>long term synaptic depression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>long-term synaptic potentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>operant conditioning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>grooming behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of circadian sleep/wake cycle, sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mating behavior</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="15">
      <id>BE0000650</id>
      <name>5-hydroxytryptamine receptor 7</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>18996971</pubmed-id>
            <citation>Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov  7.</citation>
          </article>
          <article>
            <pubmed-id>19509219</pubmed-id>
            <citation>Toohey N, Klein MT, Knight J, Smith C, Teitler M: Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol Pharmacol. 2009 Sep;76(3):552-9. doi: 10.1124/mol.109.056283. Epub 2009 Jun 9.</citation>
          </article>
          <article>
            <pubmed-id>20827463</pubmed-id>
            <citation>Teitler M, Toohey N, Knight JA, Klein MT, Smith C: Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P34969" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 7</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.</specific-function>
    <gene-name>HTR7</gene-name>
    <locus>10q21-q24</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>84-104
118-138
158-178
202-222
237-257
326-346
368-388</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.97</theoretical-pi>
    <molecular-weight>53554.43</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5302</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U68487</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1857143</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>12</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>12</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P34969</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT7R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-7</synonym>
      <synonym>5-HT-X</synonym>
      <synonym>Serotonin receptor 7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001296|5-hydroxytryptamine receptor 7
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTW
DAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLI
VSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDR
YLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYT
IYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE
ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSC
IPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK
LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010453|5-hydroxytryptamine receptor 7 (HTR7)
ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTT
CTGCCAGAAGTGGGGCGCGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTC
GCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG
GACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAG
AAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGC
CTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC
GTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTC
ACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAATGTCTTCATCGCC
ATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG
TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG
AAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA
TGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG
ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC
CAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA
GTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA
GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG
CGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG
CTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC
ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC
CCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG
TGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG
CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCTACAAAATGCTGACTACTGTAGAAAA
AAAGGTCATGATTCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood circulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Human</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10048600</pubmed-id>
            <citation>Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51.</citation>
          </article>
          <article>
            <pubmed-id>19910717</pubmed-id>
            <citation>Hendset M, Molden E, Refsum H, Hermann M: Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009 Dec;29(6):537-41. doi: 10.1097/JCP.0b013e3181c17df0.</citation>
          </article>
          <article>
            <pubmed-id>19902987</pubmed-id>
            <citation>Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.</citation>
          </article>
          <article>
            <pubmed-id>19817501</pubmed-id>
            <citation>Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000.</citation>
          </article>
          <article>
            <pubmed-id>19934256</pubmed-id>
            <citation>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970.  Epub 2009 Nov 24.</citation>
          </article>
          <article>
            <pubmed-id>11560868</pubmed-id>
            <citation>Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <title>Drug Interactions: Cytochrome P450 Drug Interaction Table</title>
            <url>http://medicine.iupui.edu/clinpharm/ddis/table.asp</url>
          </link>
          <link>
            <title>Source</title>
            <url>http://www.healthscout.com/rxdetail/68/110/8/main.html</url>
          </link>
        </links>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
    <name>Cytochrome P450 2D6</name>
    <general-function>Steroid hydroxylase activity</general-function>
    <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
    <gene-name>CYP2D6</gene-name>
    <locus>22q13.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>7.26</theoretical-pi>
    <molecular-weight>55768.94</molecular-weight>
    <chromosome-location>22</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP2D6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M20403</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181350</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1329</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P10635</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP2D6_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYP2DL1</synonym>
      <synonym>CYPIID6</synonym>
      <synonym>Cytochrome P450-DB1</synonym>
      <synonym>Debrisoquine 4-hydroxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonic acid epoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>coumarin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>isoquinoline alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cellular organofluorine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="2">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Human</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10048600</pubmed-id>
            <citation>Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51.</citation>
          </article>
          <article>
            <pubmed-id>19934256</pubmed-id>
            <citation>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970.  Epub 2009 Nov 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <title>Drug Interactions: Cytochrome P450 Drug Interaction Table</title>
            <url>http://medicine.iupui.edu/clinpharm/ddis/table.asp</url>
          </link>
        </links>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
    <name>Cytochrome P450 3A4</name>
    <general-function>Vitamin d3 25-hydroxylase activity</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
    <gene-name>CYP3A4</gene-name>
    <locus>7q21.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions>2-22</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.25</theoretical-pi>
    <molecular-weight>57342.67</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP3A4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M18907</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1337</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08684</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP3A4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
      <synonym>1.14.13.-</synonym>
      <synonym>Albendazole monooxygenase</synonym>
      <synonym>Albendazole sulfoxidase</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYP3A3</synonym>
      <synonym>CYPIIIA3</synonym>
      <synonym>CYPIIIA4</synonym>
      <synonym>Cytochrome P450 3A3</synonym>
      <synonym>Cytochrome P450 HLp</synonym>
      <synonym>Cytochrome P450 NF-25</synonym>
      <synonym>Cytochrome P450-PCN1</synonym>
      <synonym>Nifedipine oxidase</synonym>
      <synonym>Quinine 3-monooxygenase</synonym>
      <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vitamin D3 25-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>albendazole monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>quinine 3-monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vitamin D 24-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>testosterone 6-beta-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>androgen metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcitriol biosynthetic process from calciol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin D metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="3">
      <id>BE0002362</id>
      <name>Cytochrome P450 3A5</name>
      <organism>Human</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>19934256</pubmed-id>
            <citation>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970.  Epub 2009 Nov 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <title>Drug Interactions: Cytochrome P450 Drug Interaction Table</title>
            <url>http://medicine.iupui.edu/clinpharm/ddis/table.asp</url>
          </link>
        </links>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20815" source="Swiss-Prot">
    <name>Cytochrome P450 3A5</name>
    <general-function>Oxygen binding</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
    <gene-name>CYP3A5</gene-name>
    <locus>7q21.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.09</theoretical-pi>
    <molecular-weight>57108.065</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2638</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP3A5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J04813</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181346</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1338</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P20815</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP3A5_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>CYPIIIA5</synonym>
      <synonym>Cytochrome P450 HLp2</synonym>
      <synonym>Cytochrome P450-PCN3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004639|Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5)
ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG
CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT
GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT
GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA
GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA
AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG
AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC
ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT
CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG
TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC
CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT
TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA
ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC
AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT
GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT
CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT
AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA
CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT
GGAGAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="4">
      <id>BE0003612</id>
      <name>Cytochrome P450 3A7</name>
      <organism>Human</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <title>Drug Interactions: Cytochrome P450 Drug Interaction Table</title>
            <url>http://medicine.iupui.edu/clinpharm/ddis/table.asp</url>
          </link>
        </links>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P24462" source="Swiss-Prot">
    <name>Cytochrome P450 3A7</name>
    <general-function>Oxygen binding</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
    <gene-name>CYP3A7</gene-name>
    <locus>7q21-q22.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.59</theoretical-pi>
    <molecular-weight>57525.03</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2640</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D00408</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>220149</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P24462</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP3A7_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>CYPIIIA7</synonym>
      <synonym>Cytochrome P450-HFLA</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006949|Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019448|Cytochrome P450 3A7 (CYP3A7)
ATGGATCTCATCCCAAACTTGGCCGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGATA
CTCCTCTATCTATATGGAACCCGTACACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATGCTTTGTCCTTCCGTAAGGGCTATTGGACGTTT
GACATGGAATGTTATAAAAAGTATAGAAAAGTCTGGGGTATTTATGACTGTCAACAGCCT
ATGCTGGCTATCACAGATCCCGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTCGGGCCAGTGGGATTTATGAAAAATGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGAATACGATCATTGCTGTCTCCAACATTCACCAGCGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAACACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAGCATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTAATCCATTAGATCCATTCGTT
CTCTCAATAAAAGTCTTTCCATTCCTTACCCCAATTCTTGAAGCATTAAATATCACTGTG
TTTCCAAGAAAAGTTATAAGTTTTCTAACAAAATCTGTAAAACAGATAAAAGAAGGTCGC
CTCAAAGAGACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT
TCAAAAGACTCTGAGACCCACAAAGCTCTGTCTGATCTGGAGCTCATGGCCCAATCAATT
ATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAAGTGCAGAAGGAAATTGATACAGTTTTACCC
AATAAGGCACCACCCACCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT
GTTGAAATCAATGGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTT
CTTCATCATGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGGTTCAGT
AAAAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA
AACTGCATTGGCATGAGGTTTGCTCTCGTGAACATGAAACTTGCTCTAGTCAGAGTCCTT
CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTACGCTTTGGA
GGACTTCTTCTAACAGAAAAACCCATTGTTCTAAAGGCTGAGTCAAGGGATGAGACCTTT
GTAGATATGGAGCCCATTCACATGGACTTTTTAAGAAGCTTGGCATTCCAGGGCCCACAC
CTCTGCTTTTTTTGGGAACTACTTTGTCCTACCATCAGATCCCGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>